CerSci Therapeutics   Report issue

For profit Phase 1
Founded: Dallas TX United States (2015)
Status: Acquired by Acadia Pharmaceuticals (2020)

Organization Overview

First Clinical Trial
2019
NCT04175743
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CerSci Therapeutics

Active Ingredients

Drugs in Phase 1 Trials (1)

ct-044 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 1